PMID- 11251341
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20171101
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 30 Suppl 2
DP  - 2000
TI  - Physiological function of tissue factor pathway inhibitor and interaction with 
      heparins.
PG  - 48-56
AB  - Tissue factor pathway inhibitor (TFPI) is now recognized as a major physiological 
      anticoagulant. Its main role is to modulate factor VIIa/tissue factor catalytic 
      activity. Another important role is to potentiate the effect of heparins. TFPI is 
      released from the vascular endothelium after injection of either unfractionated 
      heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide 
      high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. In 
      dilute prothrombin-time-based assays, released TFPI contributes approximately 
      one-third to the anticoagulant effect of heparin, the remaining being accounted 
      for by antithrombin. Released TFPI, but not plasma TFPI, contains the basic 
      carboxy-terminal tail which is important for the anticoagulant effect. UFH and 
      LMWH exert differential effects on intravascular TFPI. UFH, but not LMWH, given 
      in therapeutic doses, is associated with a progressive depletion of TFPI, which 
      is associated with a strong rebound activation of coagulation after cessation of 
      treatment. Such depletion may explain the apparent superior efficacy of LMWH 
      observed in clinical trials.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Sandset, P M
AU  - Sandset PM
AD  - Department of Haematology, Haematological Research Laboratory, Ullevaal 
      University Hospital, Oslo, Norway. p.m.sandset@ioks.uio.no
FAU - Bendz, B
AU  - Bendz B
FAU - Hansen, J B
AU  - Hansen JB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 4C905MSK4W (Hexadimethrine Bromide)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/chemistry/*metabolism
MH  - Antithrombins/physiology
MH  - Chemical Fractionation
MH  - Endothelium, Vascular/metabolism
MH  - Factor Xa Inhibitors
MH  - Glycosaminoglycans/pharmacology
MH  - Heparin/chemistry/*metabolism
MH  - Heparin, Low-Molecular-Weight/metabolism
MH  - Hexadimethrine Bromide/pharmacology
MH  - Humans
MH  - Lipoproteins/chemistry/*physiology
MH  - Models, Biological
MH  - Prothrombin Time
MH  - Structure-Activity Relationship
RF  - 66
EDAT- 2001/03/17 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/03/17 10:00
PHST- 2001/03/17 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/03/17 10:00 [entrez]
AID - 54163 [pii]
AID - 10.1159/000054163 [doi]
PST - ppublish
SO  - Haemostasis. 2000;30 Suppl 2:48-56. doi: 10.1159/000054163.